Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Jänne, Pasi A ^a   Skarin, Arthur T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant therapy; Carboplatin; Cisplatin; Docetaxel; Multimodality therapy; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA;

EID: 0036304079     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.s.012     Document Type: Article

References (30)

1. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: Long-term follow-up in 41 patients
2. Multimodality therapy for stage IIIA/IIIB non-small cell lung cancer
3. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
4. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
5. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
6. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
7. Preliminary results of a phase III trial in regionally advanced; unresectable non-small-cell lung cancer
8. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer
9. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
10. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
11. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
12. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
13. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer (NSCLC)
14. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer
15. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
16. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
17. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
18. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
19. Early results of an international phase III study evaluating Taxotere as neo-adjuvant therapy for radically-resectable stage III NSCLC
20. Pathologic stage IIIB non-small cell lung cancer (NSCLC): Prolonged survival with consolidation docetaxel following concurrent chemotherapy (SWOG 9504)
21. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIB non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival
22. Phase I study of docetaxel with concomitant thoracic radiation therapy
23. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial
24. A phase I/II study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC)
25. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial
26. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIB non-small-cell lung carcinoma
27. A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (LA-NSCLC)
28. Phase II trial of induction carboplatin (CAR) and docetaxel (DOC) with concurrent radiation (RT) in early-stage non-small cell lung cancer (NSCLC)
29. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC)
30. A phase I study of carboplatin (car) and docetaxel (doc) followed by weekly car/doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC)